ArticleCancer cell international2026
Multi-omics data reveal B cell regulated immune heterogeneity of MIF signaling pathway in uveal melanoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTebentafusp, a T-cell receptor (TCR)-based therapeutic agent, has emerged as a groundbreaking treatment for uveal melanoma (UM), particularly in cases of metastatic UM. While this innovation has significantly improved patient prognosis, the development of additional therapeutic strategies remains crucial. This study aims to explore the role of the B-cell receptor (BCR) in the pathogenesis of UM, with the goal of identifying it as a potential target for future treatments.
methodsBoth bulk RNA-seq and single-cell RNA-seq (scRNA-seq) datasets were collected for comprehensive analysis. The TRUST4 algorithm was employed to reconstruct and analyze the BCR repertoire in UM samples, enabling the evaluation of BCR clonal diversity in the bulk RNA-seq analysis. Additionally, blood samples from a UM cohort at Beijing Tongren Hospital, comprising 5 primary and 5 metastatic UM patients, were collected and subjected to proteomic analysis. In the clinical cohort and the scRNA-seq analyses, a combination of differentially expressed gene (DEG) identification, gene set enrichment analysis (GSEA), and cell-cell communication network analysis was utilized to elucidate key signaling pathways involved in UM progression. UM cell lines were adopted to verify the role of Migration Inhibitory Factor (MIF)-CD74 in the tumor.
resultsAnalysis using the TRUST4 algorithm revealed that UM samples exhibited lower clonal diversity, as indicated by various diversity indices. Notably, certain IGK, IGH, IGL-V, and J genes were significantly highly expressed in UM samples, suggesting a critical role of BCR in UM pathogenesis (P < 0.05). Clinically, patients with primary UM demonstrated a smaller largest basal diameter (11.3 ± 1.2 mm vs. 13.4 ± 2.8 mm) and reduced tumor height (7.1 ± 2.2 mm vs. 8.2 ± 2.1 mm) compared to metastatic cases. Proteomic analysis of blood samples identified a total of 3,188 proteins, with 164 upregulated and 232 downregulated (P < 0.05). Functional enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) highlighted the enrichment of BCR-related signaling pathways in UM blood samples. Furthermore, scRNA-seq analysis confirmed differential expression of V and J genes across B-cell subtypes. Specifically, plasma B cells were found to regulate the MIF signaling pathway through interactions between the receptor CXCR4 and CD74 in metastatic UM. Downregulating MIF-CD74 could relief tumor cell proliferation in primary and metastatic UM cells.
conclusionsOur findings demonstrate that specific V and J genes within the BCR repertoire provide new insights into the underlying mechanisms of UM, particularly in metastatic UM. Both proteomic and scRNA-seq analyses revealed activation of the MIF signaling pathway in metastatic UM samples, mediated through the interaction with CD74, which has been verified in UM cell lines. These discoveries shed light on potential novel therapeutic strategies for UM, offering promising directions for future treatment development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.